Holen Sie sich die Stockscreener-App
6.99
0.00%
0.00
Schlusskurs vom Vortag:
$6.99
Offen:
$6.99
24-Stunden-Volumen:
266.37K
Relative Volume:
0.14
Marktkapitalisierung:
$573.54M
Einnahmen:
$414.29M
Nettoeinkommen (Verlust:
$-99.81M
KGV:
-5.2367
EPS:
-1.3348
Netto-Cashflow:
$-28.65M
1W Leistung:
+0.00%
1M Leistung:
+0.29%
6M Leistung:
+85.41%
1J Leistung:
-27.19%
1-Tages-Spanne:
$6.99
$7.00
1-Wochen-Bereich:
$6.98
$7.00
52-Wochen-Spanne:
$3.08
$9.67
Accolade Inc Stock (ACCD) Company Profile
Firmenname
Accolade Inc
Sektor
Branche
Telefon
610-834-2989
Adresse
660 W. GERMANTOWN PIKE SUITE 500, PLYMOUTH MEETING
Vergleichen Sie ACCD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACCD
Accolade Inc
|
6.99 | 573.54M | 414.29M | -99.81M | -28.65M | -1.3348 |
|
VEEV
Veeva Systems Inc
|
226.94 | 37.08B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
57.78 | 10.64B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
49.08 | 8.13B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
88.68 | 7.54B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
37.08 | 6.36B | 906.14M | -52.62M | 89.62M | -0.3621 |
Accolade Inc Stock (ACCD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-28 | Bestätigt | Needham | Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-17 | Fortgesetzt | DA Davidson | Neutral |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-05-24 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-04-12 | Eingeleitet | Stephens | Overweight |
| 2023-03-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-02-09 | Herabstufung | Jefferies | Buy → Hold |
| 2023-02-02 | Eingeleitet | Raymond James | Outperform |
| 2022-09-08 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-09-07 | Eingeleitet | Truist | Buy |
| 2022-08-12 | Eingeleitet | DA Davidson | Buy |
| 2022-05-02 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-04-29 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-04-29 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-04-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-04-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-04-29 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Eingeleitet | Wells Fargo | Underweight |
| 2022-04-07 | Eingeleitet | Guggenheim | Neutral |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-02-11 | Eingeleitet | Goldman | Buy |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-09-30 | Eingeleitet | Berenberg | Buy |
| 2021-09-17 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-05-28 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-05-06 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-04-15 | Eingeleitet | Needham | Buy |
| 2021-03-11 | Fortgesetzt | Goldman | Buy |
| 2021-01-15 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-01-07 | Eingeleitet | BTIG Research | Buy |
| 2020-12-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-09-22 | Eingeleitet | DA Davidson | Buy |
| 2020-07-27 | Eingeleitet | BofA Securities | Buy |
| 2020-07-27 | Eingeleitet | Credit Suisse | Neutral |
| 2020-07-27 | Eingeleitet | Goldman | Buy |
| 2020-07-27 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-27 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-27 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-07-27 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Accolade Inc Aktie (ACCD) Neueste Nachrichten
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Accolade, Inc. (ACCD) - ACCESS Newswire
Is Accolade Inc. (NASDAQ:ACCD) the Best Performing Stock So Far In 2025? - MSN
Accolade, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Accolade (ACCD) - ACCESS Newswire
Accolade shareholders approve merger with Transcarent By Investing.com - Investing.com South Africa
Accolade Stockholders Approve Merger with Transcarent - TipRanks
Accolade Shareholders Greenlight Merger With Transcarent - MarketScreener
Accolade shareholders approve merger with Transcarent - Investing.com India
Accolade Stockholders Approve Merger Between Accolade and Transcarent - GlobeNewswire
Major Healthcare Deal: Accolade Shareholders Green-Light Transcarent Merger as Company Plans Private Future - Stock Titan
GLAZER CAPITAL, LLC Acquires Significant Stake in Accolade Inc - GuruFocus
Accolade president Robert Cavanaugh sells $1,264 in stock By Investing.com - Investing.com Australia
Accolade CFO Stephen H. Barnes sells $991 worth of stock By Investing.com - Investing.com Australia
Accolade CEO Rajeev Singh sells $2,018 in stock By Investing.com - Investing.com Australia
Accolade president Robert Cavanaugh sells $1,264 in stock - Investing.com India
Accolade CEO Rajeev Singh sells $2,018 in stock - Investing.com India
Accolade CFO Stephen H. Barnes sells $991 worth of stock - Investing.com
STOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of ACCD, SKGR, AVAV, WMPN to Act Now - The Malaysian Reserve
Do Options Traders Know Something About Accolade (ACCD) Stock We Don't? - Barchart
AcCOLADE CFO Stephen Barnes sells $1,769 in stock By Investing.com - Investing.com Canada
Accolade Inc Stock: $621M Transcarent Buyout Sends Shares Soaring - sharewise
Accolade president Robert Cavanaugh sells shares worth $1,734 By Investing.com - Investing.com Canada
$HAREHOLDER ALERT: The M&A Class Action Firm Urges Stockholders of ACCD, SKGR, AVAV, WMPN to Act Now - GlobeNewswire Inc.
AcCOLADE CFO Stephen Barnes sells $1,769 in stock - Investing.com India
Accolade president Robert Cavanaugh sells shares worth $1,734 - Investing.com
Accolade Being Investigated on Behalf of Accolade, Inc. Investors. Contact Levi & Korsinsky For Details. - ACCESS Newswire
Accolade, Inc. (NASDAQ:ACCD) Stake Boosted by Rhumbline Advisers - Defense World
Analysts Set Accolade, Inc. (NASDAQ:ACCD) Target Price at $6.51 - Defense World
Accolade (NASDAQ:ACCD) Cut to “Hold” at Piper Sandler - Defense World
Accolade Welcomes Oshi Health to Trusted Partner Ecosystem – Company Announcement - Financial Times
Can This Virtual GI Care Partnership Solve the $136B Digestive Health Crisis? - Stock Titan
Accolade president Robert Cavanaugh sells $3,828 in stock - Investing.com Australia
Accolade CEO Rajeev Singh sells $7,802 in company stock By Investing.com - Investing.com Australia
Accolade’s CFO sells $3,577 in stock to cover tax obligations By Investing.com - Investing.com South Africa
Accolade EVP Richard Eskew sells $2,623 in company stock By Investing.com - Investing.com Australia
Accolade CEO Rajeev Singh sells $7,802 in company stock - Investing.com India
Accolade president Robert Cavanaugh sells $3,828 in stock By Investing.com - Investing.com South Africa
Piper Sandler downgrades Accolade ahead of shareholder vote - Investing.com
Accolade EVP Richard Eskew sells $2,623 in company stock - Investing.com
Piper Sandler downgrades Accolade ahead of shareholder vote By Investing.com - Investing.com South Africa
Piper Sandler Downgrades Accolade to Neutral From Overweight, $9 Price Target -March 05, 2025 at 07:54 am EST - Marketscreener.com
Accolade’s CFO sells $3,577 in stock to cover tax obligations - Investing.com
Accolade, Crowdstrike, Marriott International - TradingView
Piper Sandler Downgrades Accolade Inc. (ACCD) to Neutral - StreetInsider
Has Accolade (ACCD) Outpaced Other Business Services Stocks This Year? - Yahoo Finance
Finanzdaten der Accolade Inc-Aktie (ACCD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Accolade Inc-Aktie (ACCD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Barnes Stephen H. | Chief Financial Officer |
Mar 17 '25 |
Option Exercise |
0.00 |
415 |
0 |
304,176 |
| Barnes Stephen H. | Chief Financial Officer |
Mar 18 '25 |
Sale |
6.99 |
142 |
992 |
304,034 |
| Cavanaugh Robert N | President |
Mar 17 '25 |
Option Exercise |
0.00 |
510 |
0 |
218,878 |
| Cavanaugh Robert N | President |
Mar 18 '25 |
Sale |
6.99 |
181 |
1,264 |
218,697 |
0.20%
3.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):